Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR

Prostate Cancer Team Cracks Genetic Code to Show Why Inherited Disease Can Turn Lethal
January 25, 2017
Health Officials Urge At-Risk Groups To Get Tested For Hepatitis C
January 26, 2017
Show all

Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR

Patients on blood thinners need to be monitored closely with INR testing while being treated for hepatitis C.

INR should be monitored closely during treatment of chronic hepatitis C with direct-acting antivirals in patients also receiving vitamin K antagonists (eg, warfarin), because of possible changes in liver function during treatment.

Read full article: Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR Drug Safety Update – GOV.UK

Read Full Article: Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR Drug Safety Update – GOV.UK

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.